DexCom, Inc. DXCM
DexCom, Inc. (Nasdaq: DXCM) is an endocrine/women's health medical device company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Dexcom G7 CGM System | continuous glucose monitoring for diabetes | device-combination | Approved |
| Dexcom G7 15 Day CGM System | continuous glucose monitoring for diabetes | device-combination | Approved |
| Stelo | biosensor for adults and children ages 2+ with prediabetes and Type 2 diabetes who do not use insulin | device-combination | Approved |
Recent results and decisions
- Oct 29, 2026positive Dexcom published the CONNECT randomized clinical trial in The New England Journal of Medicine, showcasing outcomes driven by Dexcom G7 for people with Type 2 diabetes not on insulin.
Subsequent to the quarter, published the CONNECT randomized clinical trial in The New England Journal of Medicine, showcasing outcomes driven by Dexcom G7 that redefine the standard of care for people with Type 2 diabetes not on insulin.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other endocrine/women's health companies
- Utah Medical Products Inc UTMD
- Sera Prognostics, Inc. SERA
- Femasys Inc FEMY
- Pulsenmore Ltd. PLSM
- Trinity Biotech PLC TRIB
- INVO Fertility, Inc. IVF
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.